Capricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy Deramiocel
Capricor Therapeutics shares are in the spotlight Wednesday ahead of the FDA’s November 22 decision on Duchenne therapy deramiocel.
Last updated: 2026-11-19 08:32:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Capricor Therapeutics Inc. (CAPR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.04, with a market capitalization of $488.98M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.96 to $40.37. This page covers its latest market performance, valuation, price trends and company information.
$488.98M | |
$8.64 | |
$9.46 | |
$8.00 | |
$8.41 | |
8.00M | |
4.65M | |
-- | |
$40.37 | |
$2.96 | |
-- | |
2026-09-30 |
Capricor Therapeutics Inc. (CAPR) last closed at $8.04 as of 2026-11-19 01:00:00, down 4.40% ($0.37) from the previous close of $8.41.
During the latest regular trading session, CAPR traded between $8.00 and $9.46, with a volume of 8.00M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Capricor Therapeutics Inc. (CAPR) moved from $8.87 to $8.04, representing a decline of 9.40% ($0.83).
The stock traded between $7.99 and $11.23 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 5.72 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 13.6%
CAPR is currently trading at $8.04, placing it 13.6% of the way from its 52-week low of $2.96 to its 52-week high of $40.37. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 231 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Capricor Therapeutics Inc. and CAPR stock.
Capricor Therapeutics shares are in the spotlight Wednesday ahead of the FDA’s November 22 decision on Duchenne therapy deramiocel.
Capricor Therapeutics shares are rising Tuesday ahead of the FDA's pending decision on its Duchenne muscular dystrophy therapy, deramiocel.
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Roth Capital analyst Boobalan Pachaiyappan reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Neutral and raises the price target from $7 to $10.5.
Eligible investors can buy real shares of Capricor Therapeutics Inc. (CAPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CAPR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CAPR shares and USD.
CAPR Shares to USD
1.00 CAPR shares = 8.036 USD
Calculations are estimates based on the latest available price and are for reference only.